# Clave Capital

> Clave Capital is a VC fund in Pamplona backing Biotechnology and Software. See 48 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Pamplona, Spain
- Total investments: 48
- Last investment: Jul 2026
- Lead investor: 38%
- Fund size: $53M
- Last fund: Feb 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/clave-capital/
- Website: http://clave.capital/
- Facebook: https://www.facebook.com/clave.capital/

Clave Capital is a VC fund in Pamplona focused on Biotechnology and Software. Clave is an investment management company.

## Contacts

5 contacts available for Clave Capital. Shizune tracks 2 team members at Clave Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/clave?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $462k–$5.5M |
| Series A | $3.2M–$21M |
| Venture - Series Unknown | $541k–$7.1M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 23% |
| Software | 7 | 15% |
| Health Care | 7 | 15% |
| Medical Device | 5 | 10% |
| Artificial Intelligence | 5 | 10% |

51 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 26 | 54% |
| Series A | 6 | 13% |
| Venture - Series Unknown | 5 | 10% |
| Funding Round | 3 | 6% |
| Pre-Seed | 1 | 2% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 31 | 65% |
| Chile | 1 | 2% |
| Switzerland | 1 | 2% |
| United States | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Pedro De Alava | Office Director | 7 | https://shizune.co/investors/profile/pedro-de-alava |
| Jose Javier Armendariz | CEO | 0 | https://shizune.co/investors/profile/jose-javier-armendariz |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sensesbit | Sensesbit is a SaaS market research platform focused on sensory intelligence for the food and beverage industry, developed by TasteLab to analyze and predict product market acceptance . The tool integrates advanced statistical analysis, AI for benchmarking, and computer vision tools to manage sensory testing with consumers and trained panels. Learnmore about the platform on the official Sensesbit website. | $1.1M | Venture - Series Unknown | Jul 15, 2026 |  |
| Telum Therapeutics | Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M | Series A | Jul 01, 2026 |  |
| D-Sight | D-Sight is an early treatment for the leading cause of preventable blindness in the working-age population. | $2.4M | Seed | Feb 23, 2026 |  |
| Pharmacelera | Pharmacelera is a company that applies accurate Quantum-Mechanics (QM) algorithms, Machine Learning (ML) and High-Performance Computing (HPC) to mine an unexploited chemical space and propose molecular candidates that have higher chances to become a drug. The patented computational technology derives from more than 25 years of research at theUniversity of Barcelona and it has been validated in scientific peer-reviewed publications and benchmarking studies performed by our users and customers. | $7.1M | Venture - Series Unknown | Feb 18, 2026 |  |
| Neboda | Neboda is a science and technology that aims to transform agriculture into a more sustainable, competitive, and appealing business while also producing a better and healthier product. | $2.2M | Seed | Jul 21, 2025 |  |
| Aortyx | Aortyx is a pioneer company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona that aims at providing a new generation of endovascular devices to treat vascular diseases. Our technology focuses on tissue regeneration by mimicking the aorta biomechanical environment. It provides a suitable milieu for cellmigration and proliferation in a bioresorbable platform that minimizes differences with the natural dynamics of the aorta. | $16M | Series A | Jun 12, 2025 |  |
| Semi Zabala | Semi Zabala is a power semiconductor company that uses new technologies to develop, manufacture, qualify, and market semiconductor circuits and devices for use in power electronics for high-performance and reliability applications. | $5.5M | Seed | Jun 05, 2025 |  |
| Genbioma | Evidence-based microbiome company aims to leverage the central role of probiotics and the gut microbiota on the glycemic regulation. "Microbiota" "Premium probiotics" "Long-term glycemic regulation" "Prediabetes" | $540.7K |  | Feb 11, 2025 |  |
| Genbioma | Evidence-based microbiome company aims to leverage the central role of probiotics and the gut microbiota on the glycemic regulation. "Microbiota" "Premium probiotics" "Long-term glycemic regulation" "Prediabetes" | $544.1K | Seed | Feb 11, 2025 |  |
| Corify Care | CORIFY Care is a start-up funded by main world-wide experts on cardiac arrhythmias which is going to introduce in the market a novel medical device to non-invasively map cardiac arrhythmias in real time. This novel technology will improve the treatment in more than 10 million of atrial fibrillation patients only in Europe. Our non-invasiveelectro-anatomical mapping systems displays the activation patterns in each point of the heart without the need of invasive catheters, allowing the possibility to map all atrial fibrillation patients even during a regular visit to the cardiologist. CORIFY Care is located in Madrid, Spain, one of the most attractive places to work/live on the South of Europe. | $3.2M | Venture - Series Unknown | Dec 11, 2024 |  |

10 of 48 investments shown.

## Co-investors
- [Centre for the Development of Industrial Technology (CDTI)](https://shizune.co/investors/profile/centre-for-the-development-of-industrial-technology-cdti) — VC Fund, 9 deals together
- [Clave Mayor](https://shizune.co/investors/profile/clave-mayor) — VC Fund, 8 deals together
- [SODENA](https://shizune.co/investors/profile/sodena) — VC Fund, 6 deals together
- [Invivo Capital Partners](https://shizune.co/investors/profile/invivo-capital-partners) — VC Fund, 5 deals together
- [CDTI Innovación's INNVIERTE program](https://shizune.co/investors/profile/cdti-innovaci%C3%B3n-s-innvierte-program) — VC Fund, 4 deals together
- [EASO Ventures](https://shizune.co/investors/profile/easo-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [All Investors in Spain](https://shizune.co/investors/investors-spain)
- [All VC Funds in Spain](https://shizune.co/investors/vc-funds-spain)
- [SaaS VC Funds in Spain](https://shizune.co/investors/saas-vc-funds-spain)
- [SaaS Investors in Spain](https://shizune.co/investors/saas-investors-spain)
- [Health Care Investors in Spain](https://shizune.co/investors/health-care-investors-spain)
- [Health Care VC Funds in Spain](https://shizune.co/investors/health-care-vc-funds-spain)

## FAQ

### What does Clave Capital invest in?

Clave Capital invests primarily in Biotechnology, Software and Health Care startups, most often at Seed and Series A stage. Most of the 48 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Clave Capital's check size?

Clave Capital typically joins rounds of $462k–$5.5M at Seed, $3.2M–$21M at Series A and $541k–$7.1M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Clave Capital participates in.

### How do I contact Clave Capital?

Public channels for Clave Capital include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Clave Capital?

The team at Clave Capital includes Pedro De Alava (Office Director) and Jose Javier Armendariz (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co